Cotinine Interactions: Alcohol, Caffeine, Food & Other Compounds in the Literature

Cotinine is the principal metabolite of nicotine and, because of its long half-life relative to nicotine, the compound most laboratories measure when they want an objective index of tobacco or secondhand smoke exposure. That dual identity — a molecule with its own reported biological activity, and simultaneously a measurement tool — shapes almost everything published about "cotinine interactions." A large fraction of the literature that appears to be about cotinine plus alcohol, or cotinine plus diet, is in fact about smokers who also drink, or about smoke-exposed people whose diets differ. Those are co-occurrence studies, not pharmacological interaction studies.

This page is for educational purposes only and is not medical advice; consult a licensed physician for questions about any substance, exposure or health condition. Nothing here describes a protocol, and no combination is characterised as safe or advisable. The purpose is to report what the cited papers examined.

Three Categories of "Interaction" Evidence

Reading this literature is easier once the categories are separated, because they support very different kinds of statements.

Cotinine and Alcohol

No published trial in the verified evidence set administered cotinine and alcohol together to measure a pharmacological interaction. What exists is population work in which both exposures were recorded.

A 2025 cohort analysis in the International Journal of Cancer examined alcohol and smoking habits in association with hepatocellular carcinoma risk and reported that the two habits were studied jointly rather than in isolation, reflecting how frequently they co-occur (PMID 40098437). That analysis concerned disease risk associated with the two behaviours, not the effect of ethanol on cotinine pharmacokinetics.

A separate methodological study took a different angle. Researchers compared hair analysis with self-report for alcohol, caffeine and nicotine consumption in adolescents, publishing in The American Journal of Drug and Alcohol Abuse in 2017, and reported that the biomarker approach and the questionnaire approach did not always agree for these three substances (PMID 27588338). That paper is frequently cited in discussions of alcohol–nicotine co-use, but its subject was measurement validity, not a biological interaction between the substances.

The mechanistic reasoning researchers use (labelled as such)

Where no direct study exists, investigators typically reason from shared metabolic pathways. Nicotine is converted to cotinine predominantly by hepatic CYP2A6, and chronic ethanol exposure is known in pharmacology broadly to alter hepatic enzyme expression. That is the rationale usually offered for why cotinine-to-nicotine ratios might differ between drinkers and non-drinkers. It is reasoning, not a finding, and none of the papers cited on this page tested it.

Cotinine and Caffeine

The caffeine question follows the same shape. The adolescent hair-analysis study measured caffeine alongside nicotine and alcohol and reported discrepancies between analytical detection and self-reported consumption across the substances examined (PMID 27588338). It did not administer caffeine and cotinine together, and it did not report a change in cotinine levels attributable to caffeine intake.

The mechanistic argument researchers raise here, again labelled as reasoning rather than evidence, concerns CYP1A2: caffeine is largely cleared by that enzyme, and cigarette smoke contains polycyclic aromatic hydrocarbons that induce it. Under that reasoning, the relationship runs from smoke exposure to caffeine clearance rather than from caffeine to cotinine. No paper in this citation set measured that relationship, so it is presented only as the explanation investigators invoke, not as a demonstrated effect.

Cotinine, Food and Fasting

There is no fasting or fed-state pharmacokinetic study of cotinine in the verified literature here. The food-related work is nutritional and socioeconomic in character.

An NHANES analysis covering 2003–2016 examined household food insecurity together with in-utero and early life smoke exposure and reported that these exposures were assessed in the same national dataset, with cotinine serving as the objective marker of smoke exposure (PMID 34181942). The study described how food insecurity and smoke exposure distribute together in a population; it did not test whether eating alters cotinine absorption or elimination.

A more directly biochemical nutrition paper appeared in the Journal of Periodontal Research in 2022, where researchers examined the interaction between serum vitamin C levels and smoking on periodontal condition in older adults and reported that the two factors were analysed as an interaction term rather than as independent contributors (PMID 35415888). This is one of the few papers in the set that used the word interaction in its statistical sense — a modification of one factor's association by another — and it concerned periodontal outcomes, not cotinine concentrations.

Cotinine and Nicotine Itself

The most direct combination evidence involves cotinine and its parent compound. A 2016 study in Neuroscience Letters reported that cotinine antagonised the behavioural effects of nicotine exposure in the planarian Girardia tigrina (PMID 27616704). The finding is notable because it positions the metabolite as behaviourally opposing, rather than simply mimicking, the parent molecule in that invertebrate model. Extrapolation from planarians to mammals is not supported by that paper.

A separate clinical pharmacology line of work concerned nicotine and the nicotinic antagonist mecamylamine. A 2000 paper in Clinical Pharmacology and Therapeutics examined nicotine–mecamylamine interactions in humans (PMID 10945316). That study addressed receptor-level antagonism of nicotine and is the standard reference when researchers discuss blocking nicotinic signalling; it was not a cotinine administration study.

Cotinine and Cannabidiol

The clearest metabolic interaction finding in this set involves CBD. Researchers reported in Chemical Research in Toxicology in 2023 that cannabidiol and its metabolite 7-hydroxycannabidiol inhibited nicotine metabolism (PMID 36626330). Because cotinine is the product of that metabolic step, inhibition of nicotine metabolism is mechanistically relevant to how much cotinine is formed — a point the study addressed at the enzymatic level rather than through clinical dosing of cotinine itself.

This matters for interpretation of cotinine as a biomarker. If a compound slows the conversion of nicotine to cotinine, then a measured cotinine value may under-represent nicotine intake, as the enzymology examined in that inhibition work implies (PMID 36626330).

Cotinine and Krill Oil

One preclinical study combined cotinine with a dietary supplement. Writing in Frontiers in Neuroscience in 2018, researchers reported that cotinine plus krill oil decreased depressive behaviour and increased astrocyte survival in the hippocampus of mice subjected to restraint stress (PMID 30618579). This is the one paper in the set that explicitly tested a cotinine-plus-X combination in a mammal and reported outcomes for the combination. The findings were obtained in a mouse restraint-stress model, and the study did not establish a corresponding effect in humans.

Cotinine as a Co-Exposure Marker in Cardiovascular and Cancer Research

Much of what is written about cotinine "combined with" other risk factors comes from studies where cotinine simply verified exposure status. These are worth distinguishing clearly, because they are not interaction studies at all.

• A 2018 analysis in Circulation Journal examined the relationship between cotinine-verified smoking status and incidence of hypertension in 74,743 Korean adults, using biochemical verification rather than self-report to classify participants (PMID 29491326).
• A 2022 Public Health study reported that secondhand smoke exposure was associated with abnormal P-wave axis (PMID 35247863).
• A 2023 paper in the Journal of Cancer Research and Clinical Oncology examined the association between secondhand smoke and cancers in adults in the US population (PMID 35943599).
• A 2026 multi-omics investigation in Ecotoxicology and Environmental Safety integrated epidemiology, genetics, toxicology and single-cell transcriptomics to study tobacco exposure and peripheral artery disease (PMID 41916120).

In each of these, cotinine functioned as the exposure metric. None administered cotinine, and none tested a second compound alongside it.

Cotinine Combinations: What Studies Report on Adverse Events

The verified literature does not contain a controlled human combination-safety trial of cotinine with alcohol, caffeine, food or supplements, so no adverse-event profile for such combinations can be reported from these sources. The mouse study that combined cotinine with krill oil reported behavioural and histological outcomes — reduced depressive behaviour and increased hippocampal astrocyte survival under restraint stress — rather than a toxicity endpoint (PMID 30618579). The human interaction work available here concerned nicotine and mecamylamine (PMID 10945316) and enzymatic inhibition of nicotine metabolism by CBD (PMID 36626330). Absence of reported adverse events in a set of papers that did not look for them is not evidence of absence.

How the Evidence Stacks Up

1. Strongest combination evidence: cotinine with krill oil in a mouse stress model (PMID 30618579) and cotinine against nicotine in planarians (PMID 27616704) — both preclinical.
2. Strongest metabolic evidence: CBD and 7-OH-CBD inhibiting nicotine metabolism (PMID 36626330).
3. Statistical interaction evidence: serum vitamin C and smoking on periodontal condition (PMID 35415888).
4. Co-occurrence only: alcohol and smoking in liver cancer risk (PMID 40098437), caffeine–alcohol–nicotine hair versus self-report (PMID 27588338), and food insecurity with early-life smoke exposure (PMID 34181942).

Readers comparing sources should note that the volume of literature mentioning cotinine is very large, but the volume testing cotinine as an administered agent alongside another compound is small. For background on the molecule itself, see the cotinine overview in the learn section.

References

• Nicotine-mecamylamine interactions (Clinical Pharmacology and Therapeutics, 2000)
• Secondhand smoke exposure is associated with abnormal P-wave axis (Public Health, 2022)
• Alcohol and smoking habits in association with hepatocellular carcinoma risk (International Journal of Cancer, 2025)
• Relationship Between Cotinine-Verified Smoking Status and Incidence of Hypertension in 74,743 Korean Adults (Circulation Journal, 2018)
• Household food insecurity and in-utero and early life smoke exposure: Data from NHANES 2003-2016 (Preventive Medicine, 2021)
• Tobacco exposure and peripheral artery disease: A multi-omics investigation integrating epidemiology, genetics, toxicology, and single-cell transcriptomics (Ecotoxicology and Environmental Safety, 2026)
• Alcohol, caffeine, and nicotine consumption in adolescents: hair analysis versus self-report (The American Journal of Drug and Alcohol Abuse, 2017)
• Cotinine antagonizes the behavioral effects of nicotine exposure in the planarian Girardia tigrina (Neuroscience Letters, 2016)
• Association between secondhand smoke and cancers in adults in the US population (Journal of Cancer Research and Clinical Oncology, 2023)
• Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD) (Chemical Research in Toxicology, 2023)
• Cotinine Plus Krill Oil Decreased Depressive Behavior, and Increased Astrocytes Survival in the Hippocampus of Mice Subjected to Restraint Stress (Frontiers in Neuroscience, 2018)
• Interaction between serum vitamin C levels and smoking on the periodontal condition in older adults (Journal of Periodontal Research, 2022)